Thursday 29 January 2026 07:00 [PST] 10:00 [EST] 15:00 [GMT] In this webinar, presented in association with the journal mAbs, Drs. Crescioli and Reichert discuss recent trends in antibody therapeutics development and forecast key events that may occur in 2026. They will begin with a brief review of approvals from 2025, the product candidates with marketing applications under consideration and investigational antibodies – including bispecifics and antibody-drug conjugates – forecast to enter regulatory review by the end of 2026. They will also discuss benchmarks for the time typically required for clinical development and regulatory review based on recently approved antibody therapeutic products stratified by their therapeutic area, mechanism of action, format and country of origin. [ui-tabs] [ui-tab title=”REGISTER NOW”] If you are unable to view the form on the page below, you can access it here. [/ui-tab] [ui-tab title=”What will you learn?”] What will you learn? Trends in antibody therapeutics development How investigational early-stage antibody research is being translated into tangible clinical outcomes Clinical phase and approval success rates for unconventional antibody formats such as bispecifics and ADCs Projections for investigational antibody therapeutics approvals in 2025 and 2026 The annual ‘Antibodies to Watch’ articles published in mAbs from 2010 to 2025 can be found here. [/ui-tab] [ui-tab title=”Who this may interest”] Who this webinar may interest: Antibody enthusiasts Research scientists Strategic intelligence experts Portfolio managers [/ui-tab] [ui-tab title=”Speakers”] Speakers Silvia Crescioli Independent Consultant Silvia Crescioli is an independent consultant specializing in business intelligence and science communication for antibody therapeutic research…
